Phase 4 N=577 Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel
Influenza
Primary: Post-vaccination Geometric Mean Titer Against Influenza Virus A/H1N1 — 173.1; 83.9 titers
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 BLI4700-202: A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects
Colonoscopy
Primary: Proportion of Subjects With Successful Bowel Preparation — 15 Participants
N/A N=77 A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: The Proportion of Patients for Whom the Intended Treatment Was Feasible — 70 Participants
Phase 2 N=145 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by…
N/A N=44 Effects of Osteopathic Manipulative Treatment and Bio Electro-Magnetic Regulation Therapy on Neck Pain in Adults
Neck Pain
Primary: Neck Pain Rating Neck Disability Index (NDI) — 13; 7.4; 12.2; 11.2 units on a scale
N/A N=36 Young Adult Congenital Heart Disease Physical Activity Lifestyle Study (YACHD-PALS)
Cardiovascular Disease Other · Physical Activity
Primary: Moderate to Vigorous Physical Activity (MVPA) — -0.7; 8.8 Average change in minutes per day — p=.023
Phase 3 N=40 Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Marginal Proportion (Expressed as Percentage) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell…
Phase 2 N=57 Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Central Nervous System Pathology
Primary: Overall Diagnostic Preference — 10; 34; 56; 26 Percentage of participants — p=<0.0001
Phase 3 N=377 Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)
Non Cystic Fibrosis Bronchiectasis
Primary: Mean Annual Non-cystic Fibrosis Bronchiectasis (NCFB) Pulmonary Exacerbation Rate — 0.580; 0.948 number of Pulmonary Exacerbations — p=0.00101
Phase 2 N=100 Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
RSV Infection
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic…
N/A N=160 Multilevel Family Planning Intervention
Contraceptive Usage
Primary: Number of Couples With Uptake of Any High Efficacy Contraceptive Method — 20; 9; 15; 26 Couple — p=0.20
N/A N=18 Resiliency Among Older Adults Receiving Lung Cancer Treatment
Advanced Lung Carcinoma · Extensive Stage Lung Small Cell Carcinoma · Stage IIIA Lung Cancer AJCC v8
Primary: Recruitment Rates — 11 Participants
Phase 2 N=114 A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects
Colonoscopy
Primary: Number and Percentage of Subjects With Successful Bowel Cleansing — 35; 36; 16; 19 Participants
N/A N=105 Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion
ST Elevation Myocardial Infarction
Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)